Mianserin

In a double-blind, placebo-controlled trial in adults with depressive illness, mianserin produced significant antidepressant effects and improved sleep from the first night of treatment, with prominent sedation and drowsiness but no serious cardiotoxic or anticholinergic complications reported.

In healthy adult volunteers, single and repeated doses of mianserin produced dose-dependent sedation and impairment of psychomotor performance and vigilance in the hours after dosing, while vital signs remained largely stable and serious adverse events were not observed.

In healthy adult volunteers, single and repeated doses of mianserin produced dose-dependent sedation and impairment of psychomotor performance and vigilance in the hours after dosing, while vital signs remained largely stable and serious adverse events were not observed.

In a double-blind, placebo-controlled trial in adults with depressive illness, mianserin produced significant antidepressant effects and improved sleep from the first night of treatment, with prominent sedation and drowsiness but no serious cardiotoxic or anticholinergic complications reported.

Using polysomnography in adults with depressive illness, mianserin administration reduced sleep latency, increased total sleep time and sleep efficiency, and produced strong subjective sedation, with no major cardiopulmonary adverse events over the study period.

In a double-blind, placebo-controlled trial in adults with depressive illness, mianserin produced significant antidepressant effects and improved sleep from the first night of treatment, with prominent sedation and drowsiness but no serious cardiotoxic or anticholinergic complications reported.

In a study of healthy adult volunteers given oral mianserin for several weeks, platelet 5-HT2 receptor density increased and ligand affinity decreased, while platelet serotonin content and uptake sites remained unchanged, indicating systemic serotonergic receptor modulation without major clinical adverse effects in this population.

Using polysomnography in adults with depressive illness, mianserin administration reduced sleep latency, increased total sleep time and sleep efficiency, and produced strong subjective sedation, with no major cardiopulmonary adverse events over the study period.

In a double-blind, placebo-controlled trial in adults with depressive illness, mianserin produced significant antidepressant effects and improved sleep from the first night of treatment, with prominent sedation and drowsiness but no serious cardiotoxic or anticholinergic complications reported.

In healthy adult volunteers, single and repeated doses of mianserin produced dose-dependent sedation and impairment of psychomotor performance and vigilance in the hours after dosing, while vital signs remained largely stable and serious adverse events were not observed.

In a double-blind, placebo-controlled trial in adults with depressive illness, mianserin produced significant antidepressant effects and improved sleep from the first night of treatment, with prominent sedation and drowsiness but no serious cardiotoxic or anticholinergic complications reported.

Using polysomnography in adults with depressive illness, mianserin administration reduced sleep latency, increased total sleep time and sleep efficiency, and produced strong subjective sedation, with no major cardiopulmonary adverse events over the study period.

In healthy adult volunteers, single and repeated doses of mianserin produced dose-dependent sedation and impairment of psychomotor performance and vigilance in the hours after dosing, while vital signs remained largely stable and serious adverse events were not observed.

Using polysomnography in adults with depressive illness, mianserin administration reduced sleep latency, increased total sleep time and sleep efficiency, and produced strong subjective sedation, with no major cardiopulmonary adverse events over the study period.